IOVA 8-K: Corporate Presentation Attached (Aug 29, 2025)

Rhea-AI Filing Summary

Iovance Biotherapeutics, Inc. (IOVA) submitted an 8-K reporting other events and provided a corporate presentation as an exhibit. The filing lists written and soliciting communications under Rule 425 and Rule 14a-12, plus pre-commencement communications under Rules 14d-2(b) and 13e-4(c). The disclosure includes Exhibit 99.1, a corporate presentation dated August 29, 2025, and an Inline XBRL cover page. The document is signed by Frederick G. Vogt, Ph.D., J.D. in his capacity as Interim CEO, President, and General Counsel.

Positive

• Exhibit 99.1 corporate presentation was attached and made publicly available (August 29, 2025)

Negative

• None.

Insights

Corporate Governance Analyst

TL;DR: The company filed an 8-K attaching a corporate presentation and noted pre-commencement and solicitation communications.

Iovance disclosed procedural communications under securities rules and attached a corporate presentation dated August 29, 2025. Those references indicate the company is documenting outreach activities that are typically part of transaction-related or solicitation processes, though no transaction details are included in this filing.

Dependencies include any underlying transaction, shareholder vote, or solicitation timeline that would be described elsewhere; absent additional filings, the presentation itself is the next document to check for material disclosures within days to weeks.

Investor Relations Specialist

TL;DR: A corporate presentation was made public via Exhibit 99.1; investors should review it for strategic updates.

The attached Exhibit 99.1 is a primary source for updated corporate messaging and may contain operational, strategic, or market-positioning slides. The 8-K formalizes availability of that presentation to investors.

Reviewing the presentation on or soon after August 29, 2025 will show whether there are material updates; if not, no immediate financial impact is disclosed in this filing.

false 0001425205 0001425205 2025-08-29 2025-08-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 29, 2025

IOVANCE BIOTHERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State of Incorporation)
001-36860		75-3254381
Commission File Number		(I.R.S. Employer Identification No.)
825 Industrial Road, Suite 100
San Carlos, California		94070
(Address of Principal Executive Offices)		(Zip Code)
(650) 260-7120
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.000041666 per value	IOVA	The Nasdaq Stock Market, LLC

Item 8.01 Other Events.

On August 29, 2025, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company’s presentation that it intends to use at such events is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Iovance Biotherapeutics, Inc., Corporate Presentation – August 2025
104		Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 29, 2025	Iovance Biotherapeutics, Inc.
	By:	/s/ Frederick G. Vogt
		Name:	Frederick G. Vogt, Ph.D., J.D.
		Title:	Interim CEO, President, and General Counsel

FAQ

What did IOVA disclose in the 8-K dated August 29, 2025?

The company reported other events and attached a corporate presentation (Exhibit 99.1) dated August 29, 2025; it also noted written and soliciting communications under specified securities rules.

Does the filing announce a merger or acquisition for IOVA?

No specific merger or acquisition is disclosed in this 8-K; the filing references solicitation and pre-commencement communication rules but includes no transaction details.

Who signed the 8-K for Iovance (IOVA)?

The filing is signed by Frederick G. Vogt, Ph.D., J.D. in his roles as Interim CEO, President, and General Counsel.

Where can investors find the corporate presentation mentioned in the 8-K?

The presentation is included as Exhibit 99.1 to the 8-K and is dated August 29, 2025; investors can access it through the SEC filing or the company’s investor relations page.

Which SEC rules are cited in the filing?

The filing cites Rule 425 (written communications), Rule 14a-12 (soliciting material), Rule 14d-2(b), and Rule 13e-4(c) (pre-commencement communications).